Japan records surprise trade deficit in July as exports weaken further
In a recent transaction, Austin Aerts, the Chief Financial Officer of Sera Prognostics , Inc. (NASDAQ:SERA), sold 4,818 shares of the company’s Class A common stock. This sale, executed on March 7, 2025, was valued at approximately $19,850, with shares sold at a weighted average price of $4.12. The transaction was part of a block trade, with prices ranging from $4.02 to $4.33. The sale comes as SERA’s stock has experienced a significant decline, down nearly 47% year-to-date, with the current price showing notable distance from its 52-week high of $12.36.
The sale was conducted to cover tax withholding obligations related to the vesting of restricted stock units, as mandated by Sera Prognostics. Following this transaction, Aerts holds 309,702 shares directly. According to InvestingPro data, the company maintains strong liquidity with a current ratio of 2.11 and is scheduled to report earnings on March 19, 2025. For deeper insights into SERA’s financial health and valuation metrics, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.
In other recent news, Sera Prognostics has announced the termination of its "at-the-market" stock offering prospectus, which was intended to raise up to $50 million through the sale of Class A common stock. The company has not utilized this offering and has the option to initiate a new offering in the future. In a separate development, Sera Prognostics has launched a public offering of Class A common stock and pre-funded warrants, with underwriters having the option to purchase an additional 15% of the shares. The proceeds from this offering are intended to support U.S. commercial operations, EU expansion, and FDA approval efforts for its PreTRM test.
The offering is managed by Jefferies, TD Cowen, William Blair, and RBC Capital Markets. Additionally, Sera Prognostics has disclosed that the Society for Maternal Fetal Medicine has published an abstract with topline results from the PRIME study, which focuses on improving neonatal outcomes through prematurity risk assessment. The study’s detailed findings will be presented at the SMFM 2025 Pregnancy Meeting later this month. Following the presentation, the company will host a conference call and live webcast to discuss the study results in more detail. These developments reflect Sera Prognostics’ active engagement in capital-raising and research efforts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.